AstraZeneca

A call to action from CEOs to accelerate climate action Our CEO Pascal Soriot has joined over 100 CEOs and senior executives from World Economic Forum's (WEF) Alliance of CEO Climate Leaders to call for more ambitious policies and greater collaboration to drive climate action. The WEF Alliance CEO Climate Leaders letter urges world leaders to: 🤝 Develop ambitious Nationally Determined Contributions (NDCs) 🤝 Scale up climate finance 🤝 Remove obstacles to deliver on COP28 pledges 🤝 Support breakthrough technologies The impacts of the climate emergency are resulting in a public health crisis. We must come together to avoid every fraction of global warming and create a healthier future. #COP29 #WhatScienceCanDo Read the CEO Climate Leaders letter: https://learn.az/6042UNhAw

Despite significant progress in breast cancer awareness, detection and care, it remains the leading cause of cancer deaths among women worldwide. Global inequities in care result in vast differences in patient outcomes both within and across countries depending on who a patient is and where they live. By making breast cancer care a global health priority now, we can transform outcomes for people living with breast cancer in the future. #BreastCancerAwarenessMonth #HealthEquity

Better life chances can lead to better health outcomes, especially for women in underserved communities. 🌍 Our Young Health Programme in India launched RISE to upskill young women in Chennai & Bangalore. What started as a small project now helps them realise their potential. 🌟 https://learn.az/6042U2e9r #GirlsBelongHere2024 #WhatScienceCanDo Plan_India

As we approach the World Health Summit 2024, Michel Demaré, Chair of the Board at AstraZeneca, advocates for health policies that transcend political cycles to ensure the sustainable delivery of healthcare. In an article published this week in ‘Health: a Political Choice - Building Resilience and Trust’ Michel highlights: - The health of a population is a strategic asset that can yield enormous benefits for people, societies, economies, and the planet. - Investment must be targeted to facilitate the most positive change, such as screening, early detection and care pathway coordination, as well as innovation and R&D. - Health inequalities must be addressed as not only a moral imperative, but also to ensure strong health systems that serve all. Transformation in these areas could significantly decrease the burden non-communicable diseases, which pose one of the greatest challenges to health systems. Through collaboration, we can build health systems that are more equitable, sustainable, and resilient, improving the lives of billions. Link to the full article: https://learn.az/6043UsmEZ #WHS2024 #InterConnectedHealth #Sustainableinvestment

For too long, chronic respiratory diseases have been underprioritised, underfunded and undertreated. Our scientific strategy is to develop innovative new therapies to dig deep into the underlying biology and explore novel targets involved in disease driving mechanisms. Maria Belvisi, Senior Vice President and Head of Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, recently discussed our transformational approach to chronic respiratory disease with Fierce Pharma. Access the full sponsored video: https://learn.az/6048UlLZg

Our Oncology and BioPharmaceuticals R&D leaders, Susan Galbraith and Sharon Barr, have been recognised in Endpoints News’ Women in Biopharma 2024 report for their outstanding contributions to biopharmaceutical research. Endpoints News’ Women in Biopharma report celebrates the most influential women in the biopharmaceutical industry, recognising those who have made significant impacts through their work and leadership. Under their leadership, we’re helping to transform patient outcomes by improving our understanding of disease biology and developing the next generation of medicines. This recognition highlights their achievements and commitment to advancing gender equality in the pharmaceutical industry. Congratulations! #WhatScienceCanDo

Two of our largest and most advanced manufacturing sites in China and Sweden have been recognised by the World Economic Forum (WEF) as part of the Global Lighthouse Network. This prestigious designation underscores how we are pioneering digital transformation and excellence in our global supply chain. The Global Lighthouse Network accelerates the adoption of digital technologies and AI to drive operational excellence, environmental sustainability and workforce development. Receiving this #WEF Global Lighthouse Network status is a testament to our leadership in scaling advanced digital technologies. It clearly demonstrates our dedication to delivering greater value for patients, people and the planet. https://learn.az/6049UmPTB

Asthma attacks can be physically threatening and emotionally significant for many patients, and can be fatal. People with asthma are at risk of severe exacerbations regardless of disease severity or level of control. We are working to eliminate preventable asthma attacks by advancing treatment approaches. #TransformingRespiratoryCare

Tune in to hear Iskra Reic, EVP of Vaccines and Immune Therapies, on the latest HealthBeats podcast: https://learn.az/6042URWOY Iskra discusses the rising threat of non-communicable diseases (NCDs) with journalist Lara Setrakian in Abu Dhabi, highlighting her role with the PHSSR Steering Committee. NCDs cause 41 million deaths annually, deepen health inequities, strain health systems, and cost the global economy trillions. As populations age and climate change impacts vulnerable communities, screening, early detection, and treatment are crucial. Learn more in this insightful episode!

We’re delighted to win the award for Net Zero: Operations Transformation at the 2024 Reuters Sustainability Awards 🎉 AstraZeneca is recognised for driving deep decarbonisation across our operations and fleet through our over $1 billion Ambition Zero Carbon programme. By taking bold climate action, we aim to reduce Scope 1 and 2 greenhouse gas emissions by 98% by 2026 on the way to becoming net zero by 2045. And we’re making strong progress: by the end of 2023, we had reduced Scope 1 and 2 emissions by 67.6%. One of the ways we‘re doing this is by developing new sustainable sources of energy, including clean and renewable electricity. For example, we’re collaborating with Vanguard Renewables to enable 190 GWh per year or renewable natural gas to be used across our US sites, and in the UK, we’re partnering with Future Biogas to supply 100 GWh per year of biomethane to our UK sites. Find out more about our sustainability impact and how we’re accelerating the delivery of resilient, equitable and net zero healthcare: https://learn.az/6042UV7e8